Trial Profile
A Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b (Milademetan) in Combination With Low Dose Cytarabine (LDAC) in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Milademetan (Primary) ; Venetoclax
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2023 Status changed from completed to discontinued early due to lack of adequate response, and did not move to the Phase II portion of the study.
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 07 Apr 2022 Status changed from active, no longer recruiting to completed.